The Turkish Society of Nephrology 2020 Registry: COVID-19 Report

IF 0.2 Q4 UROLOGY & NEPHROLOGY
I. Kocyiğit, N. Seyahi, K. Ateş, G. Suleymanlar
{"title":"The Turkish Society of Nephrology 2020 Registry: COVID-19 Report","authors":"I. Kocyiğit, N. Seyahi, K. Ateş, G. Suleymanlar","doi":"10.5152/turkjnephrol.2022.22312","DOIUrl":null,"url":null,"abstract":"Objective: The Turkish Society of Nephrology Registry collects data on hemodialysis, peritoneal dialysis, and transplantation annually. Registry reports are printed every year as a booklet, and this is the 30th year of registry reports. Unlike previous years, registry reports include an additional chapter this year due to the Coronavirus Disease 2019 (COVID-19). The effects and results of the COVID-19 pandemic on kidney replacement therapies are presented in the 2020 reports. Methods: In this article, we obtained data from the Turkish Society of Nephrology 2020 registry report and summarized the coronavirus disease 2019-associated data and statistics for kidney failure with replacement therapy patients. Results: The number of patients on kidney replacement therapies was 83 350 individuals at the end of 2020. Totally, 1610 kidney replacement therapy patients were infected with severe acute respiratory syndrome coronavirus 2. Hemodialysis had the highest frequency of coronavirus disease 2019 (19.5%), followed by transplantation (12.2%) and peritoneal dialysis (8.6%). The mortality rate was highest in peritoneal dialysis patients with 29.6%, 24.4% in hemodialysis, and 11.2% in kidney transplant recipients. Conclusions: Coronavirus disease 2019 has significant effects on the survey of patients undergoing kidney replacement therapies through severe complications. © 2022 Turkish Society of Nephrology. All rights reserved.","PeriodicalId":29873,"journal":{"name":"Turkish Journal of Nephrology","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/turkjnephrol.2022.22312","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: The Turkish Society of Nephrology Registry collects data on hemodialysis, peritoneal dialysis, and transplantation annually. Registry reports are printed every year as a booklet, and this is the 30th year of registry reports. Unlike previous years, registry reports include an additional chapter this year due to the Coronavirus Disease 2019 (COVID-19). The effects and results of the COVID-19 pandemic on kidney replacement therapies are presented in the 2020 reports. Methods: In this article, we obtained data from the Turkish Society of Nephrology 2020 registry report and summarized the coronavirus disease 2019-associated data and statistics for kidney failure with replacement therapy patients. Results: The number of patients on kidney replacement therapies was 83 350 individuals at the end of 2020. Totally, 1610 kidney replacement therapy patients were infected with severe acute respiratory syndrome coronavirus 2. Hemodialysis had the highest frequency of coronavirus disease 2019 (19.5%), followed by transplantation (12.2%) and peritoneal dialysis (8.6%). The mortality rate was highest in peritoneal dialysis patients with 29.6%, 24.4% in hemodialysis, and 11.2% in kidney transplant recipients. Conclusions: Coronavirus disease 2019 has significant effects on the survey of patients undergoing kidney replacement therapies through severe complications. © 2022 Turkish Society of Nephrology. All rights reserved.
土耳其肾病学会2020年注册表:COVID-19报告
目的:土耳其肾脏病注册学会每年收集血液透析、腹膜透析和移植的数据。登记报告每年都以小册子的形式印发,这是登记报告的第30年。与往年不同,由于2019冠状病毒病(新冠肺炎),今年的登记报告增加了一章。2020年的报告介绍了新冠肺炎大流行对肾脏替代疗法的影响和结果。方法:在这篇文章中,我们从土耳其肾脏病学会2020年注册报告中获得了数据,并总结了2019年冠状病毒病相关数据和替代治疗患者肾衰竭的统计数据。结果:截至2020年底,接受肾脏替代疗法的患者人数为83350人。共有1610名肾脏替代治疗患者感染了严重急性呼吸系统综合征冠状病毒2型。2019年,血液透析感染冠状病毒的频率最高(19.5%),其次是移植(12.2%)和腹膜透析(8.6%)。腹膜透析患者的死亡率最高,分别为29.6%、24.4%和11.2%。结论:2019冠状病毒病对通过严重并发症接受肾脏替代治疗的患者的调查有显著影响。©2022土耳其肾脏病学会。保留所有权利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Turkish Journal of Nephrology
Turkish Journal of Nephrology UROLOGY & NEPHROLOGY-
CiteScore
0.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信